Literature DB >> 29078465

Pain management using patient controlled anaesthesia in adults post Nuss procedure: an analysis with respect to patient satisfaction.

Shyamsunder Kolvekar1, Hans Pilegaard2, Elizabeth Ashley1, Natalie Simon3, Joseph Grant4.   

Abstract

BACKGROUND: The Nuss procedure for correction of pectus excavatum is commonly associated with severe postoperative pain. The belief that thoracic epidural offers the best pain control has recently come under scrutiny after several studies have shown patient controlled anaesthesia (PCA) to be just as effective. Nevertheless, centres who have shifted to an exclusively PCA regime exist in the minority. We have conducted a retrospective survey of all patients who underwent the Nuss procedure at the Heart Hospital, London, where all patients are managed exclusively using PCA. The study aims to assess the efficacy and validity of our practice.
METHODS: A retrospective survey was carried out on 149 patients (139 males and 10 females), with an average age of 28, after undergoing a Nuss bar insertion. The study was conducted between August and October, 2014. The PCA technique used a 1 mg bolus dose of morphine sulphate, administered through a 5-minute lockout. There was no background infusion and no maximum dose limit in a 4-hour period. The outcome of the study measured patient satisfaction with postoperative analgesia and medication prescribed for home usage. The pre-operative provision of information with regard to patient expectations of pain was also assessed. The study is approved by the institutional ethical committee and has obtained the informed consent from every patient.
RESULTS: The majority of patients were either satisfied or extremely satisfied with the pain management received in hospital immediately following surgery. Additionally, a substantial number of patients strongly agreed that they were adequately warned about postoperative pain prior to the operation. None of the cohort specified that they experienced more pain than expected or thought that the medication prescribed for home usage was inadequate. Moreover, a small minority of patients reported postoperative long-term or chronic pain, with only one reporting that it lasted for longer than 6 months.
CONCLUSIONS: Results obtained from retrospective patient satisfaction surveys indicate high efficacy for PCA as a pain management strategy. The large majority of patients did not seek more medication for pain alleviation and found in-hospital treatment sufficient. Further, all patients agreed that they were adequately informed of pain-risk prior to surgery.

Entities:  

Keywords:  Nuss, patient controlled anaesthesia (PCA); pectus; thoracic surgery

Year:  2016        PMID: 29078465      PMCID: PMC5637879          DOI: 10.21037/jovs.2016.02.33

Source DB:  PubMed          Journal:  J Vis Surg        ISSN: 2221-2965


  13 in total

Review 1.  Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy.

Authors:  T T Horlocker
Journal:  Br J Anaesth       Date:  2011-12       Impact factor: 9.166

Review 2.  Risks and benefits of thoracic epidural anaesthesia.

Authors:  H Freise; H K Van Aken
Journal:  Br J Anaesth       Date:  2011-11-04       Impact factor: 9.166

3.  Continuous thoracic epidural block for surgery: gold standard or debased currency?

Authors:  J A W Wildsmith
Journal:  Br J Anaesth       Date:  2012-07       Impact factor: 9.166

4.  The Operative Treatment of Pectus Excavatum.

Authors:  M M Ravitch
Journal:  Ann Surg       Date:  1949-04       Impact factor: 12.969

5.  Acute pain after thoracic surgery predicts long-term post-thoracotomy pain.

Authors:  J Katz; M Jackson; B P Kavanagh; A N Sandler
Journal:  Clin J Pain       Date:  1996-03       Impact factor: 3.442

Review 6.  Comparison of the Nuss and the Ravitch procedure for pectus excavatum repair: a meta-analysis.

Authors:  Ahmed Nasr; Annie Fecteau; Paul W Wales
Journal:  J Pediatr Surg       Date:  2010-05       Impact factor: 2.545

Review 7.  Epidural analgesia versus intravenous patient-controlled analgesia following minimally invasive pectus excavatum repair: a systematic review and meta-analysis.

Authors:  Andrea M Stroud; Darena D Tulanont; Thomasena E Coates; Philip P Goodney; Daniel P Croitoru
Journal:  J Pediatr Surg       Date:  2014-02-22       Impact factor: 2.545

8.  Complications related to thoracic epidural analgesia: a prospective study in 1071 surgical patients.

Authors:  R Scherer; M Schmutzler; R Giebler; J Erhard; L Stöcker; W J Kox
Journal:  Acta Anaesthesiol Scand       Date:  1993-05       Impact factor: 2.105

9.  Pain management following the Nuss procedure: a survey of practice and review.

Authors:  W T Muhly; L G Maxwell; J P Cravero
Journal:  Acta Anaesthesiol Scand       Date:  2014-08-04       Impact factor: 2.105

10.  Early complications of the Nuss procedure for pectus excavatum: a prospective study.

Authors:  Christoph Castellani; Johannes Schalamon; Amulya K Saxena; Michael E Höellwarth
Journal:  Pediatr Surg Int       Date:  2008-04-05       Impact factor: 1.827

View more
  3 in total

1.  Surgical management of pectus excavatum in China: results of a survey amongst members of the Chinese Association of Thoracic Surgeons.

Authors:  Ruiqing Shi; Liang Xie; Gang Chen; Qi Zeng; Xuming Mo; Jiming Tang; Haiyu Zhou; Dongkun Zhang; Xiong Ye; Zihao Zhou; Dan Tian; Cheng Deng; Xiaosong Ben; Guibin Qiao
Journal:  Ann Transl Med       Date:  2019-05

2.  Knowledge, Attitudes, and Practices of Postoperative Pain Management by Nurses in Selected District Hospitals in Ghana.

Authors:  Awube Menlah; Isabella Garti; Sarah Ama Amoo; Confidence Alorse Atakro; Caleb Amponsah; Dorcas Frempomaa Agyare
Journal:  SAGE Open Nurs       Date:  2018-11-09

3.  A multimodal protocol utilizing liposomal bupivacaine rib blocks leads to opioid reduction in patients undergoing the Nuss procedure.

Authors:  Alicia L Eubanks; David F Grabski; Jessica Pollack; Daniel E Levin; Eugene McGahren; Linda W Martin; Jeffrey Gander
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.